No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
155 |
4. Check minimum number of eventsNone |
155 |
5. Include endpointsNone |
155 |
6. Filter based on genotype QC (FinnGen only) |
155 |
Control definitions (FinnGen only)
- Control exclude
- AB1_OTHER_BACTERIAL
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Listeriosis
based on the number of shared cases.
Similar with more cases:
- Other bacterial diseases
- Certain infectious and parasitic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1333 | 676 | 639 |
| Only index persons | 984 | 554 | 430 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 69.92 | 69.30 | 70.68 |
| Only index persons | 70.94 | 69.41 | 72.91 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 155 | 81 | 74 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 68.44 | 65.20 | 71.98 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 145
- Matched controls
- 1451
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
A32.7
ICD-10 Finland
Listerial sepsis
+∞
117.1
96
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
53.0
35.8
42
11
A41.9
ICD-10 Finland
Sepsis, unspecified
+∞
22.5
21
*
G01*A32.1
ICD-10 Finland
Listerial meningitis
+∞
20.3
19
*
R50.9
ICD-10 Finland
Fever, unspecified
8.7
19.4
45
71
B03XA02
ATC
darbepoetin alfa; parenteral
95.7
15.9
17
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
14.1
15.9
27
23
TK800
NOMESCO Finland
Hemodialysis
63.7
15.1
17
*
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
+∞
13.8
13
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.2
13.1
45
116
L04AX01
ATC
azathioprine; systemic
12.7
12.5
22
20
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
25.5
11.9
16
7
127
Kela drug reimbursment
Transplant complication
129.9
11.6
12
*
L04AA06
ATC
mycophenolic acid; systemic
30.7
10.9
14
5
A46
ICD-10 Finland
Erysipelas
7.5
10.6
25
39
A32.8
ICD-10 Finland
Other forms of listeriosis
+∞
10.5
10
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
20.7
10.5
15
8
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.2
10.2
74
353
C03CA01
ATC
furosemide; systemic
3.2
9.6
72
345
Z49.1
ICD-10 Finland
Extracorporeal dialysis
106.7
9.5
10
*
A41.8
ICD-10 Finland
Other specified sepsis
106.7
9.5
10
*
ZX120
NOMESCO Finland
Intravenous
5.2
9.5
30
69
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
9.3
9.4
19
23
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
17.7
8.7
13
8
A11CC03
ATC
alfacalcidol; systemic
21.6
8.6
12
6
A32.1
ICD-10 Finland
Listerial meningitis and meningoencephalitis
+∞
8.4
8
*
G00.9
ICD-10 Finland
Bacterial meningitis, unspecified
+∞
8.4
8
*
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
6.3
8.4
22
40
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
15.7
8.4
13
9
H02AB06
ATC
prednisolone; systemic
2.8
8.3
87
504
N02AA05
ATC
oxycodone; systemic
4.0
8.0
33
99
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
10.9
7.7
14
14
B03XA01
ATC
erythropoietin; parenteral
84.2
7.5
8
*
0270X
ICD-9 Finland
Other zoonotic bacterial diseases, Listeriosis[LISTERIOSIS ALIA (EI SYNNYNNÄINEN)]
+∞
7.3
7
*
Z94.0
ICD-10 Finland
Kidney transplant status
+∞
7.3
7
*
M05BA04
ATC
alendronic acid; oral
4.1
7.2
28
79
B01AA03
ATC
warfarin; systemic
2.8
7.0
54
251
N17.9
ICD-10 Finland
Acute renal failure, unspecified
7.8
6.9
15
21
N18.0
ICD-10 Finland
End-stage renal disease
42.1
6.8
8
*
WW500
NOMESCO Finland
Blood transfusion
8.5
6.8
14
18
WX892
NOMESCO Finland
Monitored bed care
4.8
6.8
22
52
I50.9
ICD-10 Finland
Heart failure, unspecified
3.3
6.8
37
138
L04AA01
ATC
[U] ciclosporin; systemic
23.8
6.8
9
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.0
6.7
27
79
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.5
6.6
77
452
J01MA02
ATC
ciprofloxacin; systemic
2.5
6.6
71
398
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.2
6.5
36
135
B01AB05
ATC
enoxaparin; parenteral
2.6
6.4
55
273
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.7
6.4
49
228
XW000
NOMESCO Finland
Bone marrow biopsy
6.3
6.4
16
28
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
5.4
6.3
18
37
ZX108
NOMESCO Finland
Inhalation
28.0
6.3
8
*
A32.9
ICD-10 Finland
Listeriosis, unspecified
+∞
6.3
6
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
+∞
6.3
6
*
L04AD02
ATC
tacrolimus; systemic (calcineurin inhibitors)
+∞
6.3
6
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.6
6.2
28
91
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
39
77
6.43
20.07
2.4
1.4
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
22
27
9.33
17.08
5.6
2.0
0.3
0.4
u/ml
0.25
14
15
22
32
7.85
14.84
2.5
1.6
1.1
0.4
ug/l
1.00
22
24
17
20
9.42
13.51
1.8
1.3
—
—
—
0
0
28
61
5.38
12.71
3.0
2.5
1.9
2.2
mmol/l
0.18
21
46
22
38
6.58
12.66
2.6
1.1
0.2
0.3
g/l
2.68
22
38
22
38
6.58
12.66
2.6
1.1
1.0
1.2
g/l
2.58
22
38
49
177
3.59
11.42
2.6
1.8
—
—
—
0
0
92
516
2.93
9.73
12.3
3.6
31.7
35.8
g/l
6.25
86
478
106
653
2.97
9.21
20.9
8.1
4.9
4.0
e9/l
1.50
95
567
14
21
7.23
9.06
1.9
1.4
—
—
—
0
0
16
28
6.26
9.00
2.4
1.5
—
—
—
0
0
22
56
4.41
8.20
1.8
1.3
—
—
—
0
0
10
11
9.65
8.17
2.5
1.6
—
—
—
0
0
19
43
4.90
8.15
3.1
1.6
—
—
—
0
0
19
43
4.90
8.15
3.1
1.6
7.8
7.7
g/l
0.04
13
33
19
43
4.90
8.15
3.1
1.6
3.5
4.0
g/l
0.69
12
33
17
36
5.18
7.85
2.1
1.0
—
—
—
0
0
13
22
6.36
7.51
2.2
1.4
—
—
—
0
0
18
42
4.72
7.44
3.2
1.6
3.6
3.2
g/l
0.47
12
34
11
16
7.32
7.25
2.2
1.4
—
—
—
0
0
16
35
4.98
7.11
4.0
2.5
—
—
—
0
0
15
31
5.25
7.09
1.7
1.9
—
—
—
0
0
60
308
2.55
7.02
3.1
2.1
4.1
3.3
mg/l
1.13
52
259
11
17
6.89
6.87
2.8
2.5
13.2
14.8
%
—
5
9
32
128
2.89
6.01
1.9
1.7
—
—
—
0
0
15
36
4.51
5.97
2.7
1.5
—
—
—
0
0
32
130
2.84
5.84
1.9
1.8
—
—
—
0
0
11
21
5.56
5.61
1.4
1.4
—
—
—
0
0
68
401
2.24
5.56
4.3
3.1
5834.6
1290.2
ng/l
1.44
63
337
74
455
2.20
5.43
5.1
3.0
—
—
—
0
0
5
0
+∞
5.23
1.0
0.0
—
—
—
0
0
5
0
+∞
5.23
1.0
0.0
—
—
—
0
0
15
40
4.04
5.23
4.3
1.6
—
—
—
0
0
26
101
2.89
5.12
8.8
2.8
0.7
2.1
mmol/l
1.13
17
81
14
36
4.18
5.11
2.7
1.6
—
—
—
0
0
92
632
2.12
4.92
20.6
4.9
1.2
1.2
mmol/l
4.85
78
522
9
10
9.47
4.85
2.7
1.7
—
—
—
0
0
8
8
10.46
4.57
5.6
2.4
—
—
—
0
0
85
580
2.03
4.48
18.4
4.4
1.2
1.2
mmol/l
3.79
79
517
11
26
4.48
4.43
1.1
1.1
—
—
—
0
0
58
351
2.04
4.21
4.7
2.9
0.2
0.4
e6/l
0.72
49
257
8
10
8.36
4.11
2.5
1.7
—
—
—
0
0
8
10
8.36
4.11
2.5
1.7
—
—
—
0
0
8
10
8.36
4.11
2.5
1.7
—
—
—
0
0
11
28
4.15
4.05
1.1
1.4
—
—
—
0
0
18
65
3.00
4.01
2.3
1.5
—
—
—
0
0
7
8
9.09
3.81
1.3
1.8
—
—
—
0
0
30
145
2.33
3.79
24.7
5.3
1.0
1.3
mmol/l
0.20
25
121
8
12
6.96
3.72
1.3
1.8
—
—
—
0
0
7
10
7.27
3.40
1.3
1.8
—
—
—
0
0
6
7
8.85
3.29
1.2
1.3
—
—
—
0
0
7
11
6.60
3.22
1.3
1.8
—
—
—
0
0
11
34
3.41
3.12
3.8
2.0
2.1
1.8
mg/l
0.31
11
29
10
29
3.62
3.10
1.8
1.2
—
—
—
0
0
7
12
6.05
3.05
1.4
1.3
—
—
—
0
0
5
5
10.27
3.00
1.2
1.0
—
—
—
0
0
71
506
1.74
2.88
5.6
4.0
49.9
49.4
ng/l
0.01
58
376
36
209
1.94
2.83
4.1
2.7
0.7
1.3
e6/l
0.92
27
114
17
73
2.49
2.76
14.7
5.7
92.4
93.9
%
0.31
17
73
34
195
1.95
2.76
3.8
2.9
3.7
2.3
e6/l
0.33
25
103
6
10
6.19
2.72
1.2
1.9
18.3
13.3
u/l
—
6
10
9
25
3.76
2.62
1.3
1.2
—
—
—
0
0
8
20
4.16
2.60
2.4
1.4
22734.5
14575.3
e6/l
—
8
10
44
284
1.77
2.46
5.7
1.9
—
—
—
0
0
6
13
4.75
2.29
2.5
2.5
3.5
3.0
u/ml
—
6
13
40
257
1.75
2.26
2.5
1.7
1090.9
1144.2
nmol/l
0.15
34
193
24
131
1.98
2.23
6.0
4.3
23.7
4.0
ug/l
0.73
19
115
72
542
1.61
2.23
10.3
3.4
—
—
—
0
0
68
511
1.59
2.09
2.5
2.0
94.5
96.2
pmol/l
0.08
37
270
7
21
3.44
1.99
1.3
1.3
—
—
—
0
0
7
21
3.44
1.99
3.0
1.3
1532.7
342.4
mu/l
—
7
21
7
21
3.44
1.99
1.3
1.3
—
—
—
0
0
5
11
4.66
1.95
1.0
1.2
—
—
—
0
0
5
11
4.66
1.95
1.0
1.0
—
—
u/ml
—
0
0
89
723
1.54
1.88
6.6
2.7
72.9
43.8
u/l
1.63
84
662
5
12
4.27
1.83
1.2
1.0
—
—
—
0
0
11
47
2.44
1.82
1.7
2.0
29.0
46.4
u/l
1.89
11
42
6
18
3.42
1.76
3.5
1.2
—
—
—
0
0
6
18
3.42
1.76
3.5
1.2
—
—
—
0
0
6
18
3.42
1.76
3.3
1.2
—
—
—
0
0
6
18
3.42
1.76
3.3
1.2
—
—
—
0
0
6
18
3.42
1.76
3.2
1.2
—
—
—
0
0
5
13
3.94
1.73
1.2
1.0
—
—
—
0
0
6
19
3.24
1.68
3.3
1.2
—
—
—
0
0
21
126
1.77
1.49
5.6
3.2
—
—
—
0
0
22
339
0.59
1.48
4.6
4.7
20.8
22.1
%
0.12
15
172
7
29
2.48
1.41
3.0
1.2
—
—
—
0
0
9
41
2.27
1.39
1.6
1.1
—
—
—
0
0
42
307
1.50
1.38
4.9
2.6
349.2
6912.1
umol/l
1.52
36
253
5
17
3.00
1.37
1.2
1.1
—
—
—
0
0
106
1167
0.71
1.13
4.9
4.7
1.4
1.5
mmol/l
0.92
97
1052
7
31
2.32
1.12
1.7
1.4
—
—
—
0
0
8
41
2.00
1.10
1.6
1.1
—
—
—
0
0
71
594
1.36
1.08
7.1
4.2
0.0
0.0
estimate
0.00
18
110
14
84
1.73
1.02
3.6
2.5
30.8
65.0
ml/min/173m2
—
5
28
108
1177
0.73
0.98
5.1
4.7
4.1
4.5
mmol/l
4.21
100
1069
111
1203
0.73
0.95
5.4
5.4
2.4
2.6
mmol/l
2.94
102
1083
103
1125
0.75
0.90
5.0
4.2
1.3
1.3
mmol/l
0.31
96
1008
10
60
1.71
0.74
1.5
1.3
—
—
—
0
0
9
58
1.59
0.71
6.6
2.1
1.4
1.1
%
—
9
58
110
1173
0.79
0.64
4.8
5.0
6.4
6.1
mmol/l
0.69
100
1050
5
30
1.69
0.62
1.4
1.6
—
—
—
0
0
68
600
1.24
0.62
8.6
5.5
0.0
0.0
estimate
0.00
18
106
68
605
1.22
0.56
7.2
4.2
0.0
0.0
estimate
0.00
17
102
40
336
1.26
0.55
9.6
4.5
0.0
0.0
estimate
0.00
18
104
69
620
1.20
0.50
3.1
2.7
—
—
—
0
0
5
82
0.60
0.47
3.0
1.7
—
—
—
0
0
22
177
1.28
0.43
1.2
1.3
11.9
9.5
u/ml
—
5
69
24
196
1.27
0.42
1.1
1.3
111.3
32.6
iu/ml
—
6
66
95
888
1.18
0.42
4.5
3.9
15.1
14.9
pmol/l
0.15
90
772
0
16
0.00
0.41
0.0
2.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
1.7
—
0
7
97
913
1.17
0.37
8.5
4.0
23.5
12.0
mm/h
5.05
92
827
21
250
0.81
0.33
1.4
1.2
0.9
1.1
u/ml
—
8
67
108
1126
0.87
0.31
7.9
6.4
42.6
40.6
mmol/mol
0.80
97
1033
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
19.1
—
0
12
0
13
0.00
0.21
0.0
1.3
—
7.9
—
0
6
15
175
0.84
0.20
1.3
1.4
—
—
—
0
0
109
1119
0.91
0.16
37.6
13.0
70.8
76.1
ml/min/173m2
1.12
97
901
15
170
0.87
0.14
17.6
8.1
—
—
—
0
0
108
1104
0.93
0.12
5.2
4.7
2.1
2.0
mu/l
0.34
100
966
49
470
1.06
0.09
8.8
4.4
—
—
—
0
0
7
63
1.12
0.08
5.4
3.1
3.8
4.3
pmol/l
—
7
53
14
148
0.94
0.02
1.4
1.3
—
—
—
0
0
119
1198
0.97
0.02
52.4
12.8
29.1
23.3
mg/l
1.21
111
924
103
1028
1.01
0.00
45.9
14.3
35.7
39.0
%
1.81
65
700
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
13.3
—
0
6
0
6
0.00
0.00
0.0
5.7
—
219.3
—
0
6
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint AB1_LISTERIOSIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| AB1_LISTERIOSIS | 4.859 [2.89, 8.17] | < 0.001 |
| Birth year | 0.999 [0.99, 1.01] | 0.824 |
During the follow-up period (1.1.1998 — 31.12.2019), 205 out of 348 females with AB1_LISTERIOSIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| AB1_LISTERIOSIS | 4.353 [2.43, 7.78] | < 0.001 |
| Birth year | 0.985 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 223 out of 356 males with AB1_LISTERIOSIS died.
Mortality risk
Mortality risk for people of age
years, who have AB1_LISTERIOSIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.565% | 0.673% |
| 5 | 3.177% | 4.698% |
| 10 | 7.736% | 11.197% |
| 15 | 14.768% | 20.144% |
| 20 | 25.68% | 32.273% |
Relationships between endpoints
↥Index endpoint: AB1_LISTERIOSIS – Listeriosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data